https://kodiak.com/
Kodiak Sciences develops next-generation therapies for retinal diseases. Explore our late-phase pipeline across a broad spectrum of diseases.
https://kodiak.com/our-pipeline/
Zenkuda is an anti-VEGF Antibody Biopolymer Conjugate (ABC ®) being developed to provide strong immediacy and high durability. Across multiple studies in high-prevalence retinal v
https://prconnect.thestreet.com/article/Kodiak-Sciences-Announces-Recent-Business-Highlights-and-Fourth-Quarter-and-Full-Year-2025-Financial-Results/69cc3328f8b61dfb6ec53b72
PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and ful
https://finance.yahoo.com/quote/KOD/
Find the latest Kodiak Sciences Inc. (KOD) stock quote, history, news and other vital information to help you with your stock trading and investing.
https://stockanalysis.com/stocks/kod/
1 day ago · A detailed overview of Kodiak Sciences Inc. (KOD) stock, including real-time price, chart, key statistics, news, and more.
https://www.reuters.com/business/healthcare-pharmaceuticals/kodiak-sciences-shares-surge-after-eye-drug-succeeds-late-stage-study-2026-03-26/
Mar 26, 2026 · Shares of Kodiak Sciences surged 68.6% to their highest in more than four years on Thursday after the drug developer's experimental drug met ‌the main goal in a l
https://www.biospace.com/press-releases/kodiak-sciences-announces-recent-business-highlights-and-fourth-quarter-and-full-year-2025-financial-results
Apr 1, 2026 · Kodiak Sciences (Nasdaq: KOD) is a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therape
https://www.marketwatch.com/investing/stock/kod
1 day ago · Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal dise
https://www.prnewswire.com/news-releases/kodiak-sciences-announces-recent-business-highlights-and-fourth-quarter-and-full-year-2025-financial-results-302730611.html
Mar 31, 2026 · Kodiak Sciences (Nasdaq: KOD) is a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therap
https://biopharmajournal.com/2024/12/09/kodiak-sciences-inc-kod-a-promising-bet-in-the-biopharmaceutical-space-with-upgraded-outlook/
Dec 9, 2024 · In the bustling arena of biopharmaceutical advancements, Kodiak Sciences Inc. (NASDAQ:KOD) is emerging as a key player, particularly in the field of retinal diseases